07.02.2025 • News

BP Wants to Sell German Refinery in Gelsenkirchen

Oil giant BP announced plans to sell its refinery in Gelsenkirchen, Germany, operating under the name Ruhr Oel. The assets to be divested include the refinery in Gelsenkirchen and DHC Solvent Chemie in Mülheim an der Ruhr, Germany.

According to BP, the process of finding a suitable buyer has already begun and the company is aiming for purchase agreements in 2025. However, the timeline for finalizing the sale and transferring the assets to a new owner will be subject to regulatory and government approvals. During the sales process, the refinery will continue to operate as usual, BP stated.

Emma Delaney, BP’s executive vice president, customers & products, commented: “BP needs to continually manage its global portfolio as we position to grow as a simpler, more focused, higher-value company. After a thorough review, we have concluded that a new owner would be better suited for the site to take it forward.”

BP said that it has carried out numerous projects to modernize the infrastructure of the refinery in Gelsenkirchen in recent years, for example, the renewal of the electricity network and the establishment of an independent steam supply.

Today, the refinery can process crude oils, produce high-quality fuels and also has the potential to manufacture biofuels and process recycled plastics.

Patrick Wendeler, CEO of BP Europa, said: “With significant investments, we have been able to substantially modernize our site in recent years. Due to its current production capabilities and its location – in the heart of Europe and particularly within the chemical cluster of North Rhine-Westphalia – it offers significant potential to a new owner supported by a highly qualified team.”

BP’s refinery at Gelsenkirchen, Germany. │ © BP
BP’s refinery at Gelsenkirchen, Germany. │ © BP

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.